Rafael Holdings Q3 net loss $32.4M ($1.36/sh) vs $1.4M loss YoY; driven by $89.9M IPR&D expense

Rafael Holdings, Inc.

2024-Q3 EPS reported -$1.26 revenue$472,000

Net loss from continuing operations of $32.4M ($1.36 diluted EPS) compared to $1.4M ($0.06) in prior-year quarter.
Q3 includes $89.9M in-process R&D expense from Cornerstone acquisition treatment, offset by $31.3M recovery of Cornerstone receivables.
Cash and marketable securities $72.4M as of April 30, 2024.
Increased Day Three Labs stake to 79% majority, began consolidating Jan 2024; Q3 R&D up to $1.5M from $0.7M.
Cyclo Therapeutics investment recorded $4.4M unrealized loss in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.